Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

Status:
Withdrawn

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.

Phase 1

Gilead Sciences